
US FDA has granted its approval to Wockhardt Ltd for marketing a generic version of 2mg, 4mg, 6mg, 8mg (and) 12mg extended-release tablets containing Ropinirole hydrochloride, used in the treatment of Parkinson's disease. Ropinirole extended release tablet is the generic name for the brand Requip XL, marketed in the US by Glaxo SmithKline. Wockhardt has announced that it will launch the product very soon. According to IMS Health, the total market for this product ...

via Medindia Health News
More READ

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/08/us-fda-approves-generic-version-of.html
No comments:
Post a Comment